THY1 and neoplasm: In addition, the miR-126 inhibitor obviously decreased the ratio of CD44+ CD90+ CD133+ cells, as well as the levels of IL-1α, SRY, Oct4, IL-6, and TGF-β in tumor tissues of mice (Figures 4(b) and 4(c)).